NCT03057145: Combination Study of Prexasertib and Olaparib in Patients With Advanced Solid Tumors

NCT03057145
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1
Drug Category: Misc Inhibitor, Serine-Threonine Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with known brain metastases, with the exception of patients with brain metastatic disease that has previously been treated and remained stable
https://ClinicalTrials.gov/show/NCT03057145

Comments are closed.

Up ↑